Korean J Urol.  2012 Jun;53(6):377-385.

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction

• Sung HH
• Lee SW

Abstract

Oral phosphodiesterase type 5 (PDE5) inhibitors have provided non-invasive, effective, and well-tolerated treatments for patients with erectile dysfunction (ED). However, many patients with ED are unresponsive to 'on-demand' PDE5 inhibitors. In addition, the lack of spontaneity and naturalness of the on-demand regimen could be a reason for decreased compliance with PDE5 inhibitors. Recently, tadalafil and udenafil were approved for low-dose daily administration for the treatment of ED. Since the introduction of the concept of daily administration of PDE5 inhibitors, several reports have supported the potential benefits of this therapy for disease modification, improvement of the treatment response in difficult-to-treat populations, spontaneity, and safety, although further research is needed to better address these hypotheses. In this article, we reviewed the daily administration of PDE5 inhibitors in terms of pharmacokinetics, safety, efficacy, and distinct features.

Keyword

Chronic; Erectile dysfunction; Phosphodiesterase 5 inhibitors

MeSH Terms

Carbolines
Compliance
Erectile Dysfunction
Humans
Male
Phosphodiesterase 5 Inhibitors
Pyrimidines
Sulfonamides
Tadalafil
Carbolines
Phosphodiesterase 5 Inhibitors
Pyrimidines
Sulfonamides

Reference

1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Construction of a surrogate variable for impotence in the Massachusetts Male Aging Study. J Clin Epidemiol. 1994. 47:457–467.

2. Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D, Montorsi F, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010. 57:804–814.

3. Eardley I, Donatucci C, Corbin J, El-Meliegy A, Hatzimouratidis K, McVary K, et al. Pharmacotherapy for erectile dysfunction. J Sex Med. 2010. 7(1 Pt 2):524–540.

4. McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006. 332:589–592.

5. Goldstein I, Kim E, Steers WD, Pryor JL, Wilde DW, Natanegara F, et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med. 2007. 4:166–175.

6. McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol. 2006. 50:215–217.

7. Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone. 2005. 7:57–65.

8. Carson CC, Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. 2005. 96:257–280.

9. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med. 2004. 1:292–300.

10. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med. 2005. 2:415–425.

11. Porst H, Giuliano F, Glina S, Ralph D, Casabe AR, Elion-Mboussa A, et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006. 50:351–359.

12. Rajfer J, Aliotta PJ, Steidle CP, Fitch WP 3rd, Zhao Y, Yu A. Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. Int J Impot Res. 2007. 19:95–103.

13. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med. 2008. 25:138–146.

14. Magheli A, Burnett AL. Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol. 2009. 6:415–427.

15. Ricardi U, Gontero P, Ciammella P, Badellino S, Valentino F, Munoz F, et al. Efficacy and safety of tadalafil 20 mg on demand vs. tadalafil 5 mg once-a-day in the treatment of post-radiotherapy erectile dysfunction in prostate cancer men: a randomized phase II trial. J Sex Med. 2010. 7:2851–2859.

16. Wrishko R, Sorsaburu S, Wong D, Strawbridge A, McGill J. Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. J Sex Med. 2009. 6:2039–2048.

17. Zhao C, Kim SW, Yang DY, Kim JJ, Park NC, Lee SW, et al. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2011. 60:380–387.

18. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract. 2002. 56:453–459.

19. Coward RM, Carson CC. Tadalafil in the treatment of erectile dysfunction. Ther Clin Risk Manag. 2008. 4:1315–1330.

20. Rosen RC, Padma-Nathan H, Shabsigh R, Saikali K, Watkins V, Pullman W. Determining the earliest time within 30 minutes to erectogenic effect after tadalafil 10 and 20 mg: a multicenter, randomized, double-blind, placebo-controlled, at-home study. J Sex Med. 2004. 1:193–200.

21. Porst H, Padma-Nathan H, Giuliano F, Anglin G, Varanese L, Rosen R. Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 2003. 62:121–125.

22. Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol. 2006. 61:280–288.

23. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998. 159:2164–2171.

24. Porst H, Rajfer J, Casabe A, Feldman R, Ralph D, Vieiralves LF, et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med. 2008. 5:2160–2169.

25. Shabsigh R, Donatucci C, Costabile R, Perelman MA, Burns P, Zeigler H, et al. Reliability of efficacy in men with erectile dysfunction treated with tadalafil once daily after initial success. Int J Impot Res. 2010. 22:1–8.

26. Kang DH, Lee JY, Park SY, Moon HS, Jeong TY, Yoo TK, et al. Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study. Korean J Urol. 2010. 51:647–652.

27. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Jünemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008. 101:1279–1283.

28. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med. 2008. 25:37–44.

29. Zumbe J, Porst H, Sommer F, Grohmann W, Beneke M, Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol. 2008. 54:204–210.

30. Kim BH, Lim HS, Chung JY, Kim JR, Lim KS, Sohn DR, et al. Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. Br J Clin Pharmacol. 2008. 65:848–854.

31. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, et al. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012. 9:271–281.

32. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008. 54:924–931.

33. Donatucci CF, Wong DG, Giuliano F, Glina S, Dowsett SA, Watts S, et al. Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin. 2008. 24:3383–3392.

34. Kloner RA, Jackson G, Hutter AM, Mittleman MA, Chan M, Warner MR, et al. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol. 2006. 97:1778–1784.

35. Cote RH. Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. Int J Impot Res. 2004. 16:Suppl 1. S28–S33.

36. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med. 2006. 3:12–27.

37. Gorkin L, Hvidsten K, Sobel RE, Siegel R. Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int J Clin Pract. 2006. 60:500–503.

38. Escaravage GK Jr, Wright JD Jr, Givre SJ. Tadalafil associated with anterior ischemic optic neuropathy. Arch Ophthalmol. 2005. 123:399–400.

39. Fraunfelder FW, Pomeranz HD, Egan RA. Nonarteritic anterior ischemic optic neuropathy and sildenafil. Arch Ophthalmol. 2006. 124:733–734.

40. Cordell WH, Maturi RK, Costigan TM, Marmor MF, Weleber RG, Coupland SG, et al. Retinal effects of 6 months of daily use of tadalafil or sildenafil. Arch Ophthalmol. 2009. 127:367–373.

41. Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20 mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9-month study. Eur Urol. 2008. 53:1058–1065.

42. Jarvi K, Dula E, Drehobl M, Pryor J, Shapiro J, Seger M. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol. 2008. 179:1060–1065.

43. Rubio-Aurioles E, Kim ED, Rosen RC, Porst H, Burns P, Zeigler H, et al. Impact on erectile function and sexual quality of life of couples: a double-blind, randomized, placebo-controlled trial of tadalafil taken once daily. J Sex Med. 2009. 6:1314–1323.

44. Althof SE, Rubio-Aurioles E, Kingsberg S, Zeigler H, Wong DG, Burns P. Impact of tadalafil once daily in men with erectile dysfunction--including a report of the partners' evaluation. Urology. 2010. 75:1358–1363.

45. Seftel AD, Buvat J, Althof SE, McMurray JG, Zeigler HL, Burns PR, et al. Improvements in confidence, sexual relationship and satisfaction measures: results of a randomized trial of tadalafil 5 mg taken once daily. Int J Impot Res. 2009. 21:240–248.

46. Hatzichristou D, Rosen RC, Broderick G, Clayton A, Cuzin B, Derogatis L, et al. Clinical evaluation and management strategy for sexual dysfunction in men and women. J Sex Med. 2004. 1:49–57.

47. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994. 151:54–61.

48. Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB. Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care. 2002. 25:1458–1463.

49. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med. 2006. 3:883–891.

50. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med. 1998. 15:821–825.

51. Hotta Y, Hattori M, Kataoka T, Ohno R, Mikumo M, Maeda Y, et al. Chronic vardenafil treatment improves erectile function via structural maintenance of penile corpora cavernosa in rats with acute arteriogenic erectile dysfunction. J Sex Med. 2011. 8:705–711.

52. Lee CH, Kim HS, Goo MJ, Kang KK, Ahn BO, Kim SH, et al. Chronic administration of udenafil, a selective phosphodiesterase type 5 inhibitor, promotes erectile function recovery in an animal model of bilateral cavernous nerve crush injury. J Sex Med. 2011. 8:1330–1340.

53. van der Wielen GJ, van Putten WL, Incrocci L. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys. 2007. 68:479–484.

54. Turner SL, Adams K, Bull CA, Berry MP. Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. Urology. 1999. 54:124–129.

55. van der Wielen GJ, Mulhall JP, Incrocci L. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. Radiother Oncol. 2007. 84:107–113.

56. Shabsigh R, Seftel AD, Rosen RC, Porst H, Ahuja S, Deeley MC, et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 2006. 68:689–696.

57. Nagao K, Kobayashi H, Fujikawa K, Tachibana T, Iwamoto Y, Ishii N, et al. Vardenafil allows successful intercourse initiated rapidly after dosing in Japanese patients with diabetes mellitus and erectile dysfunction. J Sex Med. 2009. 6:2851–2857.

58. Seftel A, Goldfischer E, Kim ED, Dula E, Zeigler H, Burns P. Onset of efficacy of tadalafil once daily in men with erectile dysfunction: a randomized, double-blind, placebo controlled trial. J Urol. 2011. 185:243–248.

59. Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, et al. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. J Sex Med. 2009. 6:2547–2560.

60. Aversa A, Caprio M, Rosano GM, Spera G. Endothelial effects of drugs designed to treat erectile dysfunction. Curr Pharm Des. 2008. 14:3768–3778.

61. Rosano GM, Aversa A, Vitale C, Fabbri A, Fini M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005. 47:214–220.

62. Konstantinopoulos A, Giannitsas K, Athanasopoulos A, Spathas D, Perimenis P. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother. 2009. 10:155–160.

63. Porst H, Glina S, Ralph D, Zeigler H, Wong DG, Woodward B. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. J Sex Med. 2010. 7:3487–3494.

64. La Vignera S, Condorelli RA, Vicari E, D'Agata R, Calogero AE. Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation. Int J Impot Res. 2011. 23:200–205.

65. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007. 177:1071–1077.

66. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008. 180:1228–1234.

67. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008. 53:1236–1244.

68. Porst H, Kim ED, Casabe AR, Mirone V, Secrest RJ, Xu L, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011. 60:1105–1113.

69. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012. 61:917–925.

70. Stroberg P, Hedelin H, Bergström A. Is sex only for the healthy and wealthy? J Sex Med. 2007. 4:176–182.

71. Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009. 6:2032–2038.